FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: A longitudinal study with 6 months of followup

1. Ramírez, J.
2. Fernández-Sueiro, J.L.
3. López-Mejías, R.
4. Montilla, C.
5. Arias, M.
6. Moll, C.
7. Alsina, M.
8. Sanmarti, R.
9. Lozano, F.
10. Cañete, J.D.